Shots:
- The companies will initiate P-I/II study evaluating the safety and preliminary efficacy of BBP-398 in combination with both Opdivo as dual therapy & Opdivo + KRASG12C inhibitor as triplet therapy in NSCLC patients with KRAS mutations, as 1L & 2L treatment options
- BridgeBio will sponsor the study while BMS will provide nivolumab to the study. Both the companies will share the cost of clinical development activities for the combination study
- BridgeBio is currently advancing its P-I trial in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes
Click here to read full press release/ article | Ref: BridgeBio | Image: BridgeBio
The post BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations first appeared on PharmaShots.
